本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Kerry Logistics Network Limited ('KLN'; Stock Code 0636.HK) has formed a joint venture, POSCO Flow (Thailand), through Kerry Siam Seaport ('KSSP'), its subsidiary in Thailand, with POSCO Flow, the logistics arm of POSCO Group, the largest steelmaker in South Korea. Under the partnership, KLN will act as the preferred logistics partner of POSCO Flow (Thailand) and provide comprehensive port and logistics support to POSCO Group's subsidiaries in Thailand as well as other markets in Southeast Asia. KSSP has been serving POSCO Group since 2017 for all their nominated vessels in Thailand, providing services including port, warehousing, transportation, customs clearance, stuffing/unstuffing, stevedoring and container freight. POSCO Group, a Fortune 500 company, has production facilities in 16 countries across Asia, the Americas, Africa, Europe and Oceania. The joint venture in Thailand will be a blueprint to further KLN and POSCO Group's collaboration and strengthen both companies' steel logistics capabilities in Southeast Asia and worldwide. Ellis Cheng, Executive Director and Chief Financial Officer of KLN, said, "The establishment of POSCO Flow (Thailand) is a milestone in the long-term collaboration between KLN and POSCO Group. Through this partnership, we not only support POSCO Group's expansion into Thailand's logistics market but also enhance the service capabilities of both companies, leveraging KLN's proven track record and solid presence in Southeast Asia and worldwide. The joint venture is a testament to the service excellence of KSSP and enables KLN to set new benchmarks in industrial logistics." Ha Jong-beom, Head of Steel Logistics of POSCO Flow, said, "This joint venture will enable us to secure a competitive advantage in the steel logistics market in Thailand and lay the foundation for expanding our business to the Southeast Asian market. Through this cooperation with KSSP, we will strive to provide the best logistics solutions to the companies under POSCO Group in the region and contribute to their cost competitiveness." KSSP is a multi-purpose deep sea port located at the heart of ASEAN that provides wide berth docking, container operations and warehousing services in one strategic location, serving the industrial estates on Thailand's eastern seaboard and in the Greater Mekong Region. Its joint venture with POSCO Flow marks a major step in the extension of KLN's industrial project logistics footprint in Asia. -End- About Kerry Logistics Network Limited (Stock Code 0636.HK)KLN is an Asia-based, global 3PL with a highly diversified business portfolio and extensive coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics, international freight forwarding (air, ocean, road, rail and multimodal) and e-commerce to industrial project logistics and infrastructure investment. With a global presence across 59 countries and territories, KLN has established a solid foothold in half of the world's emerging markets. Its diverse infrastructure, extensive coverage in international gateways and local expertise span across the Mainland of China, India, Southeast Asia, the CIS, Middle East, LATAM and other locations. KLN generated a revenue of over HK$47.4 billion in 2023. It is listed on the Hong Kong Stock Exchange and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index.
【2025年2月20日】在現代資料中心與關鍵 IT 管理需求日益增長的背景下，Millitronic 推出 I-NAS（Inference - Network Attached Storage），一款高效能網路附加儲存設備。I-NAS 具備即時監控、安全管理與簡易部署功能，可大幅提升 IT 基礎架構的智慧化水平，並強化自動化管理與安全性。 前瞻科技助攻綠色 IT 發展 I-NAS 採用 ARM/NPU 邊緣運算架構，相較於傳統 x86 CPU 系統，其功耗降低 60%，顯著減少能源消耗和碳排放，助力企業達成環境、社會及治理（ESG）目標。此外，I-NAS 具備即時監控及無縫互動功能，優化整體基礎設施管理。其內建 AI 周界警報系統，使用者可依據自身需求設定安全邊界，並透過姿態與人臉辨識技術精準偵測異常行為，全方位提升網路安全防護能力。 遠端監控與高效資料儲存，實現智慧管理 I-NAS 支援 RSTP 多流低延遲網路服務，結合直覺式 2D 地圖介面，使用者可輕鬆配置 IP 攝影機，提高監控精準度。設備搭載企業級 SSD，並支援 RAID 0/1 配置，確保高效的影像備份與 AI 資料處理能力。此外，Samba 協定提供持續錄影功能，而 AI 智慧搜尋技術可快速回溯影像並進行即時分析。 卓越效能與可靠性，滿足 AI 密集型應用需求 高效能神經運算：採用 ARM/NPU 架構，確保低功耗運行，最大功耗低於 18W，適用於 AI 密集型應用。 低延遲多媒體串流處理：優化即時影像處理能力，使 APC IP 攝影機 NBPD0165 的延遲降低至僅 1 秒。 企業級 SSD 儲存：提供高耐用性、快速讀寫效能，並支援長時間連續錄影。 未來展望：推動企業智慧化與永續發展 憑藉高效能 AI 運算、先進影像辨識技術及強大的資料儲存能力，I-NAS 在能源效率、邊緣運算及安全監控領域表現卓越。隨著資料中心與 IT 監控需求持續增長，I-NAS 將成為推動企業智慧化與永續發展的重要動力。
Forms strategic partnership with Korea Investment & Securities, signifying ambition to further grow CLI's private credit portfolio in South Korea Deploys KRW 40 billion loan for a data centre development in Guro, Seoul SEOUL, South Korea, Feb. 20, 2025 /PRNewswire/ -- CapitaLand Investment Limited (CLI), a leading global real asset manager, has closed its first South Korea private credit fund with a total equity commitment of KRW 180 billion[1] (S$169.2 million[2]), increasing its funds under management in its focus market of South Korea to S$3.1 billion. The CapitaLand Korea Investment No. 1 Private Equity Fund (PEF) will invest in construction, asset-backed or mortgage loans for diversified asset classes such as data centre, lodging, office or residential in gateway cities in South Korea. CapitaLand Investment's PEF has deployed a KRW 40 billion loan for the development of a data centre (pictured) in Guro, Seoul. With positive demand-supply dynamics and 30 megawatts of power secured, the data centre is well-positioned to capture demand when completed in 3Q 2028. CLI has formed a strategic partnership with Korea Investment & Securities (KIS), a subsidiary of a major financial conglomerate Korea Investment Holdings, to jointly manage PEF as co-general partners. CLI holds an 11% sponsor stake in PEF, which is in line with its asset-light strategy to grow its funds under management while keeping strong alignment with investors. PEF has deployed a KRW 40 billion loan for the development of a data centre in Guro, Seoul. The Guro district is a key data centre cluster in the west of Seoul, five kilometres from Yeouido Business District. The cluster hosts several leading cloud companies as well as IT and financial companies. With positive demand-supply dynamics and 30 megawatts of power secured, the data centre is well-positioned to capture demand when completed in 3Q 2028. SK Ecoplant, which has a credit rating of A-, will deliver the project and provide completion guarantee. SK Ecoplant is the construction and engineering arm of SK Group – one of the largest conglomerates in South Korea. KT Cloud Corp., a subsidiary of South Korea's telecommunications giant KT Corp, will lease and operate the data centre. Mr Matthew Sohn, CLI's Chief Executive Officer for Korea, said: "The strong institutional participation in PEF is testament to the network and trust CLI has built over more than 20 years of operating in the country. Leveraging CLI's deep understanding of South Korea's real estate investment landscape across multiple asset classes, we are able to expand our suite of fund products and identify suitable investment opportunities to meet investors' demand." "CLI has been fast-tracking its growth in private credit and its entry into South Korea's private credit segment is in line its investment strategy that focuses on the theme of 'Disruption'. Despite the gradual decline in interest rates, South Korean banks have been reducing their proportion of real estate loans in their portfolio[3]. As traditional lenders in South Korea become increasingly conservative, the widening funding gap creates opportunities for private lenders. Through our strategic partnership with KIS, the combination of our deal-sourcing, fund management and private credit expertise will position PEF for success. We see strong potential to scale our private credit portfolio in South Korea and remain committed to delivering long-term value for our capital partners," added Mr Sohn. CLI's expansion in private credit The launch of PEF in South Korea follows CLI's announcement in December 2024 to acquire[4] Wingate for A$200 million[5] (KRW 182.6 billion[6]). Wingate is one of Australia's leading and largest private credit investment managers. With the addition of Wingate, CLI will expand its private credit business and its portfolio in Australia. Wingate will also enlarge CLI's extensive proprietary deal origination networks and enhance its access to more institutional and private high net worth investors. In November 2024, CLI also announced the close of its Australia Credit Program (ACP). Conceived and originated in partnership with Wingate, ACP is CLI's A$265 million (KRW 241.9 billion[6]) maiden credit fund. Growing CLI's presence in South Korea With the addition of PEF, CLI manages 16 private funds in South Korea. In August 2024, CLI closed a value-add office blind pool fund in South Korea with total equity commitment of KRW 200 billion (S$188 million[2]). The private fund is a strategic partnership with KB Bank, an affiliate of the country's largest financial group, KB Financial Group. In September 2023, CLI's flagship regional core-plus fund, CapitaLand Open End Real Estate Fund, acquired a newly completed, high specifications logistics property Anseong Seongeun Logistics Centre for S$112 million (KRW 119.1 billion[7]). CLI's diversified portfolio in South Korea comprises offices, logistics facilities, lodging properties, self-storage and data centres[8]. CLI has nine serviced residences and hotels, with more than 2,400 units in Seoul, Busan, Cheongju, Incheon and Jeju, through its wholly owned lodging business unit, The Ascott Limited and its lodging trust, CapitaLand Ascott Trust. About CapitaLand Investment Limited (www.capitalandinvest.com) Headquartered and listed in Singapore, CapitaLand Investment Limited (CLI) is a leading global real asset manager with a strong Asia foothold. As at 30 September 2024, CLI had S$134 billion of assets under management, as well as S$102 billion of funds under management held via six listed real estate investment trusts and business trusts and a suite of private real asset vehicles that invest in thematic and tactical strategies. Its diversified real estate asset classes include retail, office, lodging, industrial, logistics, business parks, wellness, self-storage, data centres, private credit and special opportunities. CLI aims to scale its fund management, lodging management and commercial management businesses globally and maintain effective capital management. As the investment management arm of CapitaLand Group, CLI has access to the development capabilities of and pipeline investment opportunities from CapitaLand's development arm. As a responsible company, CLI places sustainability at the core of what it does and has committed to achieve Net Zero carbon emissions for Scope 1 and 2 by 2050. CLI contributes to the environmental and social well-being of the communities where it operates, as it delivers long-term economic value to its stakeholders. Follow @CapitaLand on social media LinkedIn: linkedin.com/company/capitaland-limitedFacebook: @capitaland / facebook.com/capitalandInstagram: @capitaland / instagram.com/capitalandX: @CapitaLand / x.com/CapitaLandYouTube: youtube.com/capitaland Important Notice This announcement and the information contained herein does not constitute and is not intended to constitute an offering of any investment product to, or solicitation of, investors in any jurisdiction where such offering or solicitation would not be permitted. [1] Includes CLI's equity contribution. [2] Based on the exchange rate of KRW 1 to S$0.000940 unless stated otherwise. [3] Source: CBRE Korea's 2024 Korea Investor Intentions Survey. [4] Plus an earn-out that is based on certain performance hurdles over a three-year period post completion of the transaction. [5] Subject to completion adjustments. [6] Based on the exchange rate of A$1 to KRW 912.925532 unless stated otherwise. [7] Based on the exchange rate of S$1 to KRW 1,063.829790 unless stated otherwise. [8] Including assets under development.
CQM200 5G NR Sub-6 物聯網模組，為數據速度和載波聚合樹立了新的基準，令其成為工業 4.0（意指第四次工業革命）、智能城市等領域高頻寬物聯網解決方案的理想選擇 聖荷西，加州, Feb. 19, 2025 (GLOBE NEWSWIRE) -- 物聯網解決方案的尖端創新企業 Cavli Wireless 欣然宣佈推出旗艦級 5G NR Sub-6 CQM200 蜂巢式物聯網模組 (Cellular IoT Module)。 CQM200 的設計旨在迎合高吞吐量連接應用的嚴格要求，提供支援高速 5G NR 連接力的物聯網應用程式。 通過推出此模組，Cavli 繼續鞏固其作為代工生產 (OEM) 開發新一代汽車解決方案值得信賴的合作夥伴地位。 CQM200 模組設計目的在於提供符合 3GPP Release 17 標準的卓越 5G NR Sub-6 效能。 CQM200 模組的大小為 45 x 52 毫米*，並以 LGA（平面網格陣列封裝）形式提供。 模組提供高達 3.7 Gbps 的超卓下載速度，以及高達 2.5 Gbps 的上載速度，滿足高吞吐量、數據繁重的物聯網應用需求。 模組以 Qualcomm SDX72 晶片組為構建基礎，整合了最為先進的組件，當中包括四核心 Arm Cortex A55 處理器及 Qualcomm Hexagon DSP 處理器，以天衣無縫的效率處理複雜的運算任務。 CQM200 的主要特徵為其三載波聚合 (3CA) 功能。 此功能容許模組聚合多個載波頻率，完善可用的無線電頻譜，以實現更高的數據傳輸速度和更佳的網絡可靠程度。 模組具有 100MHz 頻寬，即使在苛刻的條件下亦可確保持續、高質素的連線能力。 即使在網絡擠塞範圍亦要求超低延遲的應用情況，例如實時的工業控制系統、智能監控或自動駕駛汽車等，都可從 CQM200 的速度和網絡強韌性中獲益良多。 CQM200 具備全球兼容性，可支援 eSIM 技術及多星座 GNSS (L1+L5)，有助促進全球部署。 不論是資產追蹤、實時數據分析，或是其他流動定位服務，即使在最具挑戰性的環境中，此模組都能確保天衣無縫的連線能力。 包含 GNSS (全球衛星導航系統) 保證了精準的定位功能，為現代物聯網解決方案實現準確的流動定位服務。 CQM200 能滿足各行各業的需要，為物聯網應用提供變革性解決方案。 在工業 4.0 中，此模組的高吞吐量和先進處理能力，有助於對擁有眾多機器並產生大量資料數據的工業車間進行實時監察及預測性維護。 此舉令製造商可完善營運成本，並且透過採用由模組驅動的工業網關或路由器來將停工時間減至最低。 針對智能城市而言，CQM200 支援智能基礎設施，例如智能監控解決方案和公共安全系統，確保都市環境更具效率和應變能力。 於物流及運輸領域，該模組所具備的 GNSS 功能及強大的連線能力可實現準確的即時追蹤、提升營運效率，並且確保高價值資產的安全。 透過引入模組的遙距診斷、監控和調試，以及 Hubble Applet 服務（此為 Cavli Hubble 物聯網連接及數據機管理平台的先進組件），CQM200 的 Hubble 整合得以進一步提升其功能。 此功能消除了物理介入的必要性，並簡化了物聯網解決方案的擴充。 透過與全球營運商組結策略聯盟，Cavli 建立了重要的影響力，提供無與倫比的連接解決方案，在服務品質和成本效益方面樹立了新標準。 Cavli Wireless 行政總裁兼首席科技架構師 John Mathew 表示：「對於 Cavli 及物聯網行業而言，CQM200 模組的推出都標誌著一個關鍵時刻。 憑藉其 5G-NR Sub-6 功能、龐大的數據吞吐量及先進的處理能力，CQM200 的設計在於要滿足高效能應用日益複雜的需求，這些應用情況要求超低延遲的連接能力，以及可於全球各地部署的無縫可擴展性。」 透過結合先進功能和無縫的全球連接能力，Cavli 繼續為蜂巢式物聯網的可靠性、可擴展性和改革樹立新標準。 隨著物聯網格局的發展，CQM200 是對 Cavli 願景的一種體現，即實現面向未來的連線解決方案，賦予產業能力並推動科技進展。 歡迎與我們的解決方案專家聯絡，探討 CQM200 如何為您即將開始的項目增光添彩。 關於 Cavli Wireless Cavli Wireless 是一家將物聯網連接和數據管理整合至單一平台的蜂巢式物聯網模組製造商。 Cavli 旨在設計和製造工業級蜂巢式物聯網智能模組，一方面提高設備可靠性，另一方面加快應用程式開發流程。 Cavli 的智能蜂巢式模組透過整合嵌入式 eSIM 功能實現全球蜂巢式連接，亦透過專有的雲端平台 Cavli Hubble 為用戶提供經濟實惠的全球數據定價、簡化的設備管理與集中式的訂閱管理。 聯絡方式： Abhinand Dinesh 高級助理 - 企業營銷 Cavli Wireless abhinand.dinesh@cavliwireless.com +91-9605750306 https://www.cavliwireless.com/ 此公告隨附的照片可在以下網址查看：https://www.globenewswire.com/NewsRoom/AttachmentNg/ae7d10e0-8540-4ba5-b71a-2231daad0206
SYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the United States (US) Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for 67Cu-SAR-bisPSMA for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with androgen receptor pathway inhibition (ARPI). This milestone builds on Clarity's earlier receipt of 2 FTDs for the diagnostic 64Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy[1], as well as patients with biochemical recurrence (BCR) of prostate cancer following definitive therapy[2], with 2 Phase III registration trials underway (CLARIFY [NCT06056830][3] and AMPLIFY, respectively). These 3 FTDs demonstrate the quality of the data generated to date on the 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA products in addressing serious unmet needs in prostate cancer. The FTDs will enable Clarity to accelerate the development of its comprehensive program with the optimised SAR-bisPSMA agent to be used in patients with prostate cancer throughout the management of their cancer, from initial to late-stage disease, with an opportunity to completely change the entire treatment landscape for the large prostate cancer market. The FDA's FTD is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs. For SAR-bisPSMA, it provides a number of product development advantages. The designations pave the way for a faster review process once Clarity submits its product approval applications. Additionally, it enables more frequent communication with the FDA, allowing for rapid resolution of queries during development. Furthermore, Clarity can submit completed sections of its application as they are ready, rather than waiting for the entire package to be finished before it can be lodged with the FDA. These benefits would reduce the review time needed to bring this innovative and proprietary molecule to the prostate cancer imaging and therapy markets. The data for this FTD submission was based on the preliminary results to date from the Phase I/IIa SECuRE study (NCT04868604)[4], which is investigating the safety and efficacy of 67Cu-SAR-bisPSMA for the treatment of mCRPC patients. The first 3 cohorts in the dose escalation phase of the trial were successfully completed with no dose limiting toxicities (DLTs) reported in any of the participants dosed (15 participants). No adverse events (AEs) related to 64Cu-SAR-bisPSMA were observed. Most AEs related to 67Cu-SAR-bisPSMA were low grade (grade 1 or 2). The most common AE reported was mild dry mouth (grade 1, 5/15 participants, 33.3%). Preliminary data shows that the majority of participants in the SECuRE study enrolled to date had bone metastasis (77%), high median prostate-specific antigen (PSA) level at baseline (112.86 ng/mL, range 0.1-1503.1) and were heavily pre-treated (59% of participants received 3 or more lines of therapy). Despite how heavily pre-treated these participants were, and how much disease they had, 73% of them across all cohorts (including the lowest dose cohort of 67Cu-SAR-bisPSMA at 4 GBq, single dose) showed reductions in PSA levels. The majority of patients that had an increase in PSA were on the single, lowest dose cohort 1 (4 GBq). PSA reductions of greater than 50% were seen in 45% of all trial participants, despite the overwhelming majority of participants only receiving a single dose of 67Cu-SAR-bisPSMA (4, 8 or 12 GBq) in the trial. In cohorts 2, 3 and 4 (8 and 12 GBq single dose and 12 GBq multi-dose, respectively), in which most participants also only received 1 dose of 67Cu-SAR-bisPSMA, PSA reductions of greater than 35% were observed in almost 75% of participants and PSA was reduced by 80% or more in almost half of the participants so far, as patients continue in follow-up. The trial is currently progressing through the highest dose cohort where participants were administered multiple doses of 12 GBq of 67Cu-SAR-bisPSMA. Recruitment into cohort 4 is complete, and the remaining 3 participants are currently in the safety and efficacy follow-up period after receiving their first 2 doses. Following completion of the follow-up up period, the safety review committee meeting is planned for March 2025. The largest drop in prostate-specific antigen (PSA) in cohort 4 to date is a decline of 98% (from a baseline of 157.4 ng/mL). This participant, who had failed multiple lines of therapy prior to receiving 67Cu-SAR-bisPSMA (androgen deprivation therapy [ADT], ARPI and an investigational agent), has already had a radiographic partial response based on the investigator's assessment of Response Evaluation Criteria in Solid Tumours v1.1 (RECIST) criteria. Preliminary analysis showed a reduction of 60.6% in tumour volume evaluated by PSMA positron emission tomography [PET] imaging with 64Cu-SAR-bisPSMA. Cohort expansion of the SECuRE trial to assess the combination of 67Cu-SAR-bisPSMA with enzalutamide For a long time, Clarity has been working closely with many important global medical experts in the field of prostate cancer, including the Company's Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, to optimise the development of all of its products in prostate cancer. Those discussions have led to a recent protocol amendment for the SECuRE trial, which aims to investigate ways to further improve the treatment outcomes for these patients. The protocol amendment is aligned with the positive results of the Enza-p trial presented by Prof Emmett first at the European Society for Medical Oncology in 2023[5] and more recently at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium in 2025[6], which confirmed the hypothesis that targeting both androgen signalling and PSMA receptors concurrently would improve anti-cancer activity in mCRPC. The latest SECuRE protocol amendment increased the number of participants in the cohort expansion phase from 14 to 24 patients in the mCRPC pre-chemotherapy setting, with a subset of patients to receive the combination therapy of 67Cu-SAR-bisPSMA with enzalutamide. This protocol amendment has now been approved at many of the participating trial sites, and the changes are expected to further enhance the already positive results of 67Cu-SAR-bisPSMA observed in the SECuRE trial to date. This strategy focuses on the commercialisation of the product firstly in the largest market for prostate cancer therapies in mCRPC, with pre-chemotherapy being 3 times larger than the post-chemotherapy setting, and creates opportunities for the use of 67Cu-SAR-bisPSMA with a range of ARPIs in future clinical development. Addressing the radiopharmaceuticals supply issues with current treatments in such a large indication requires a streamlined approach for which Clarity's 64Cu/67Cu platform is well and uniquely suited. Clarity's Executive Chairperson, Dr Alan Taylor, commented, "Receiving 3 FTDs for the one molecule, SAR-bisPSMA, within the last 6 months is an incredible achievement for Clarity, highlighting how impressive our science and development are, the significance of the diagnostic and therapeutic data so far, and the high unmet need for better therapies and diagnostics in prostate cancer. "The dual-targeted bisPSMA molecule was developed at the benchtop of Australian science with the intent of overcoming the shortfalls of the current generation of PSMA-targeting products. It was optimised with two PSMA ligands, which increases not only the amount of product in the lesions, but also how long the product is retained in the lesions over time, making it an ideal candidate for both diagnosis and therapy. The clinical data in both diagnostic and therapeutic indications that we are generating is remarkable, confirming the results that we initially saw in preclinical development. The granting of FTDs by the US FDA for 3 distinct indications in prostate cancer that we are aiming to address with this product is testament to the incredible work of our team and collaborators. This latest FTD will allow us flexibility to develop 67Cu-SAR-bisPSMA in both pre- and post-chemotherapy patients in the mCRPC setting, with initial focus on the largest market segment. The SECuRE study will also provide invaluable information on the potential of 67Cu-SAR-bisPSMA to be combined with enzalutamide and other ARPIs in future, creating opportunities for the broader use of 67Cu-SAR-bisPSMA in those patients with such high unmet medical need. "These designations will allow us to work closely with the FDA to facilitate the development process and accelerate the approval of what could become best-in-class therapy and diagnostic agents, and our team and collaborators are committed to making this our priority in order to achieve our ultimate goal of improving treatment outcomes for people with cancer." About SAR-bisPSMA SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity's proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy. 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA have not been assessed by health authorities such as the US----- FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available. About the SECuRE trial SECuRE (NCT04868604)[4] is a Phase I/IIa theranostic trial for identification and treatment of an advanced form of prostate cancer, mCRPC. It is a multi-centre, single arm, dose escalation study with a cohort expansion. The aim of this trial is to determine the safety and tolerability of both 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA, as well as the efficacy of 67Cu-SAR-bisPSMA as a therapy. A recent protocol amendment has increased the number of participants in the cohort expansion phase from 14 to 24, and a subset of participants will receive the combination of 67Cu-SAR-bisPSMA with enzalutamide. About Prostate Cancer Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide[7]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the U.S. and around 35,770 deaths from the disease[8]. About Clarity Pharmaceuticals Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers in children and adults.www.claritypharmaceuticals.com For more information, please contact: Clarity Pharmaceuticals Dr Alan Taylor Catherine Strong Executive Chairperson Investor/Media Relations ataylor@claritypharm.com c.strong@morrowsodali.com +61 406 759 268 References 1. Clarity Pharmaceuticals. Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA. https://www.claritypharmaceuticals.com/news/fast-track/ 2. Clarity Pharmaceuticals. Clarity receives U.S. FDA Fast Track Designation for 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer. https://www.claritypharmaceuticals.com/news/ftd-2/ 3. ClinicalTrials.gov Identifier: NCT06056830, https://clinicaltrials.gov/study/NCT06056830 4. ClinicalTrials.gov Identifier: NCT04868604, https://clinicaltrials.gov/ct2/show/NCT04868604 5. Emmett et al. Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Annals of Oncology, Volume 34, S1325, 2023. 6. Emmett et al. Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901). American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, 2025 7. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21834 8. American Cancer Society: Key Statistics for Prostate Cancer, https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html This announcement has been authorised for release by the Executive Chairperson.
SINGAPORE, Feb. 17, 2025 /PRNewswire/ -- Straits Millennium Pte Ltd ("Straits Millennium"), a member of Straits Financial Group, today announced that it has obtained an in-principle approval* from the Monetary Authority of Singapore (MAS) for a Major Payment Institution (MPI) License under the Payment Services Act 2019. This significant milestone grants Straits Millennium the ability to offer digital payment token (DPT) services, reinforcing the Straits Financial Group's position as a key player in Singapore's rapidly evolving digital asset ecosystem. A Strategic Move within the Digital Asset Ecosystem As a member of the Straits Financial Group of companies—whose members provide financial services on a global scale, specializing in commodities, derivatives, and financial brokerage— Straits Millennium is uniquely positioned to bridge the gap between traditional financial markets and digital assets. This approval aligns with Singapore's vision of becoming a global digital asset hub while ensuring strong regulatory compliance and risk management. Straits Millennium's new services will enable businesses and institutional investors to navigate the complexities of digital asset transactions with confidence. Straits Millennium will provide market participants with a regulated and efficient platform to facilitate the exchange of digital payment tokens and fiat currencies, ensuring competitive trade execution and adherence to industry best practices. Straits Millennium's approach to digital asset services is anchored in compliance, security, and institutional-grade risk management. Statement from Group CEO Jeremy Ang Jeremy Ang, Group CEO of Straits Financial Group, expressed enthusiasm about this key milestone: "Securing the in-principle approval for our Major Payment Institution License is a testament to our unwavering commitment to regulatory excellence, innovation, and customer-centric solutions. Singapore has established itself as a global leader in digital asset regulation, and we are proud to play a role in shaping the future of the financial industry. With our deep expertise in derivatives, commodities, and institutional financial services, we are well- positioned to provide trusted and seamless digital asset offerings to our clients. We look forward to working closely with MAS to finalize our full license and deliver best-in-class services to the market." Enhancing Institutional Access to Digital Assets Amily Ho, Digital Assets Lead at Straits Millennium, emphasized the company's focus on institutional solutions: "The demand for compliant, seamless, and efficient digital token services continues to rise, and Straits Millennium is here to bridge that gap. Our in-principle approval allows us to build a secure and regulated ecosystem for industry players who require reliability, transparency, and scalability in their digital asset operations. Whether it's facilitating liquidity solutions or enabling efficient trading services, we are committed to delivering innovative and regulatory- compliant services that meet the evolving needs of the market." The in-principle approval marks the beginning of Straits Millennium's journey in the regulated digital asset space. The firm is actively working toward securing its full Major Payment Institution License from MAS, which will further solidify its position as a trusted and leading provider of digital asset financial services. *An in-principle approval (IPA) reflects MAS' view that a licence may be issued to the applicant upon the fulfilment of specified conditions and provided there are no material adverse developments affecting the applicant. An IPA does not constitute a licence for Straits Millennium Pte. Ltd. to provide payment services at this juncture. MAS reserves the right to rescind the IPA in circumstances where it considers appropriate. About Straits Millennium Straits Millennium is a Singapore-based digital asset financial services firm and a subsidiary of Straits Financial Group Pte Ltd. With a strong focus on regulatory compliance, institutional- grade security, and financial innovation, the company aims to bridge the gap between traditional finance and digital assets, offering seamless digital asset financial solutions tailored for today's evolving financial landscape. About Straits Financial Group At Straits Financial Group, we distinguish ourselves by promoting key and innovative contracts to support the financial and commodity derivative markets as well as providing products and services to fulfill the needs of every trader. With a strong presence in Asia and a deep understanding of the global markets, we provide value to our clients by enabling global access with a local perspective. Established in 2010, Straits Financial Group is headquartered in Singapore, and serves as the financial services arm of the CWT Group. We have established a global footprint through our presence in the United States, Indonesia, and Singapore and will continue to expand into key financial and commodity markets. For more information, please visit our website at https://www.straitsfinancial.com. About CWT Group CWT Pte. Limited, headquartered in Singapore, is a multinational corporation providing integrated logistics, commodity marketing, engineering, and financial services. It is privately held by CWT International Limited (HKEX: 521) and employs around 6,000 people worldwide. For more information, please visit our website at https://www.cwtlimited.com.
A12 藝術空間
ARM
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
